← Back to guidelines
Dermatology9 papers

Eccrine porocarcinoma

Last edited: 4/14/2026

Overview

Eccrine porocarcinoma is a rare malignant adnexal tumor originating from eccrine sweat gland acrosyringia, predominantly affecting elderly individuals with a high risk of metastasis 1.

Diagnosis

  • Clinical Presentation: Often presents as a firm, ulcerative mass, commonly in the elderly 13.
  • Histopathology: Characterized by malignant transformation of eccrine sweat gland structures 1.
  • Differential Diagnosis: Challenging differentiation from squamous cell carcinoma; useful markers include NUT expression and YAP1 fusion products 1.
  • Immunohistochemistry: Androgen receptor (AR) expression noted in about 25% of cases, typically focal/weak, more common in males 2.
  • Management

  • Primary Treatment: Wide local excision is the mainstay; Mohs micrographic surgery shows promise 1.
  • Lymph Node Management: Role of sentinel lymph node biopsy and subsequent dissection remains controversial 1.
  • Radiotherapy: Applied based on tumor characteristics and excision margins; specifics not universally standardized 13.
  • Systemic Therapy: Limited data; pembrolizumab and EGFR inhibitors show potential in advanced cases 1.
  • Special Populations

  • Elderly: Predominantly affects elderly patients, with considerations for surgical complexity and adjuvant therapies 13.
  • Unusual Locations: Cases in atypical sites like the vulva or ear require vigilant monitoring for metastasis and recurrence 34.
  • Key Recommendations

  • Surgical Excision: Wide local excision is recommended for primary treatment of eccrine porocarcinoma (Evidence: Strong 1).
  • Consideration of Mohs Surgery: Mohs micrographic surgery may be considered for optimal local control (Evidence: Moderate 1).
  • Adjuvant Radiotherapy: Use based on tumor margins and characteristics, lacking standardized guidelines (Evidence: Weak 13).
  • Sentinel Lymph Node Biopsy: Role remains undefined; decision should be individualized (Evidence: Expert opinion 1).
  • Advanced Disease: Evaluate systemic therapies like pembrolizumab and EGFR inhibitors in consultation with oncologists (Evidence: Weak 1).
  • References

    1 Bienstman T, Güvenç C, Garmyn M. Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review. International journal of molecular sciences 2024. link 2 Fernandez-Flores A, Cassarino DS. Immunoexpression of Androgen Receptors in Poroid Neoplasms. Applied immunohistochemistry & molecular morphology : AIMM 2017. link 3 Fujimine-Sato A, Toyoshima M, Shigeta S, Toki A, Kuno T, Sato I et al.. Eccrine porocarcinoma of the vulva: a case report and review of the literature. Journal of medical case reports 2016. link 4 Thompson L, Malone J, Schadt C. Erythematous nodule of the ear. Dermatology online journal 2014. link

    Original source

    1. [1]
      Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review.Bienstman T, Güvenç C, Garmyn M International journal of molecular sciences (2024)
    2. [2]
      Immunoexpression of Androgen Receptors in Poroid Neoplasms.Fernandez-Flores A, Cassarino DS Applied immunohistochemistry & molecular morphology : AIMM (2017)
    3. [3]
      Eccrine porocarcinoma of the vulva: a case report and review of the literature.Fujimine-Sato A, Toyoshima M, Shigeta S, Toki A, Kuno T, Sato I et al. Journal of medical case reports (2016)
    4. [4]
      Erythematous nodule of the ear.Thompson L, Malone J, Schadt C Dermatology online journal (2014)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG